Methods and compositions for detecting and diagnosing renal and periodontal disease - Patents.com

The method of detecting cystatin B polypeptides in samples using specific antibodies addresses the challenge of early-stage kidney disease detection, providing accurate and non-invasive diagnosis and monitoring of kidney function.

JP7598843B2Active Publication Date: 2024-12-12IDEXX LABORATORIES INC

Patent Information

Application Number
JP2021184696
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-03-02
Filing Date
2021-11-12
Publication Date
2024-12-12
Estimated Expiration
2037-03-02

AI Technical Summary

Technical Problem

Current methods for detecting early-stage kidney disease in mammals, such as dogs, are invasive or not accurate until significant tissue damage occurs, lacking effective non-invasive markers for early detection.

Method used

The method involves detecting cystatin B polypeptides in samples using specific antibodies, forming complexes under suitable conditions, and comparing the levels to control standards to diagnose renal and periodontal diseases, distinguishing between different urinary tract infections, and monitoring kidney function.

Benefits of technology

Enables early detection of kidney diseases, including acute kidney injury and chronic kidney disease, with high specificity and sensitivity, allowing for timely intervention and monitoring disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007598843000018
    Figure 0007598843000018
  • Figure 0007598843000019
    Figure 0007598843000019
  • Figure 0007598843000020
    Figure 0007598843000020
Patent Text Reader

Abstract

Compositions and methods for detecting renal and periodontal disease in mammals are provided. The present disclosure provides a method for detecting and measuring the level of cystatin B polypeptide in a sample using an antibody, and if the level is higher than that of a control, it is an indication of kidney disease or periodontal disease.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Priority This application is filed on March 2, 2016, which is incorporated by reference in its entirety. The benefit of US Patent Application No. 62 / 302,299 is claimed.

[0002] Sequence Listing This document describes the electronic text file of the sequence listing submitted electronically via EFS-Web. This text file is incorporated by reference. nal.txt", it is 7.10KB in size and was created on March 2, 2017. [Background technology]

[0003] Kidney disease is accompanied by increased fluid consumption, frequent urination, loss of appetite, weight loss, and muscle wasting. By the time clinical symptoms of kidney disease appear, irreversible kidney damage has already occurred. Early detection means early treatment. Current treatments include dialysis, phosphorus and tannin therapy, and This includes a low-carbohydrate diet. Therefore, early detection is crucial.

[0004] Renal disease progression in mammals is classified into five levels. Renal disease in mammals, e.g. dogs Current methods for detecting CKD include renal ultrasound biopsy and urinary protein / creatinine level tests. Biopsy is invasive and creatinine measurement is unlikely to result in significant tissue damage. It is only accurate until stage 3 of kidney failure occurs after the disease has progressed. What is needed is a way to detect early stage kidney disease so that treatment can be halted. Summary of the Invention

[0005] In one embodiment, a method for detecting a cystatin B ("Cys B") polypeptide in a sample is provided. The method includes the step of: 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 2 3, 24, 25, 26, or 27 One or more antibodies to a cystatin B polypeptide and SEQ ID NO: 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, or 27 (including or including) contacting the polypeptide under conditions suitable for the formation of a complex with one or more antibodies that specifically bind the polypeptide; The method includes the steps of: , 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, or 27 (including or including) Complexes with one or more antibodies that specifically bind the polypeptide are detected.

[0006] In another embodiment, a method for diagnosing renal disease in a subject is provided. determining the amount of cystatin B polypeptide in a sample from an elephant, The amount of the polypeptide is SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 2 6, or 27. The method includes determining, using one or more antibodies against cystatin B polymorphisms in a sample. The amount of peptide is compared to a control sample or a control standard to determine the level of cystatin B polypeptide in the sample. An elevated level compared to a control sample or control standard is indicative of kidney disease.

[0007] In yet another embodiment, a method of treating a disease condition in a subject is provided. The amount of cystatin B polypeptide in a sample from a subject is determined by comparing the amount of cystatin B polypeptide in a sample from a subject with SEQ ID NOs: 1, 2, 3, 4, 5, , 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2 1 consisting of (or including) 0, 21, 22, 23, 24, 25, 26, or 27 Assays for determining the presence or absence of a polypeptide using one or more antibodies that specifically bind to the polypeptide The method further comprises the steps of: requesting a test that provides a result of determining whether the sample contains cystatin B polypeptide; If the amount is higher than a control sample or control standard for the disease state, the subject is at risk for renal impairment. The disease state is characterized as acute kidney injury in patients with chronic kidney disease or Active renal impairment, acute kidney injury, active renal impairment, progressive chronic kidney disease, periodontal disease, upper urinary tract infection The disease may be a chronic condition, such as rheumatoid arthritis, ... or a combination thereof.

[0008] In yet another embodiment, a method of diagnosing periodontal disease in a subject is provided. The method comprises determining the amount of cystatin B polypeptide in a sample from a subject, The amount of tatin B polypeptide is SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, Specific for one or more polypeptides consisting of (or including) 25, 26, or 27 The method includes determining the amount of cystatin in a sample using one or more antibodies that bind to the The amount of cystatin B polypeptide in the sample is compared to a control sample or a control standard. A higher peptide level compared to a control sample or control standard is indicative of periodontal disease in the subject. It becomes.

[0009] In another embodiment, a method for distinguishing between an upper and a lower urinary tract infection is provided. The method comprises determining the amount of a cystatin B polypeptide in a sample from a subject. , the amount of cystatin B polypeptide is SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 , 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27. The method includes determining using one or more antibodies that specifically bind to the The amount of cystatin B polypeptide in the sample is compared to a control sample or a control standard. A subject having an upper urinary tract polypeptide level that is higher than a control sample or a control standard. It is a sign of infection.

[0010] In another embodiment, a method for distinguishing between acute kidney injury and a lower urinary tract infection is provided. The method includes (a) determining the amount of cystatin B polypeptide in a sample from a subject. and the amount of cystatin B polypeptide is SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 1 0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 1 that specifically binds to one or more of the polypeptides of (b) determining the amount of cystatin B polymorphism in the sample using one or more antibodies; and and comparing the amount of cystatin B peptide in the sample with a control sample or a control standard. A higher polypeptide level compared to a control sample or control standard indicates acute kidney injury in a subject. Including comparison, which is a sign of harm.

[0011] In one embodiment, the cause of the kidney disease may be chronic kidney disease, acute kidney injury, or a bacterial infection. In one embodiment, the kidney disease, chronic kidney disease, or acute kidney injury is not caused by cancer. Bacterial infections are caused by Anaplasma species, Ehrlichia species, Leptospira species, Escherichia species, or or Borrelia species. The amount of cystatin B polypeptide may be and sequence numbers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 2 7. One or more polypeptides that specifically bind to (or include) The determination can be made by detecting complexes with the antibody.

[0012] In one embodiment, the cystatin B polypeptide and SEQ ID NO: 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, or 27 (including or including) The complex with one or more antibodies that specifically bind to the polypeptide is contacted with an indicator reagent prior to detection. The one or more antibodies may be selected from SEQ ID NOs: 5, 6, 7, 11, or 13. The polypeptide may be capable of specifically binding to one or more polypeptides consisting of (or including).

[0013] In one embodiment, the subject can be a non-human animal and the sample can be serum, plasma, urine, saliva, It may be plaque, crevicular fluid, gingival biopsy, or a tongue swab.

[0014] In one embodiment, the amount of Cystatin B polypeptide or Cystatin B polypeptide is Immunoassay, competitive immunoassay, sandwich immunoassay, enzyme-linked immunosorbent assay (EIA) Lipoprotein-based immunoassay (LISA), radioimmunoassay (RIA), immunoturbidimetry, particle-enhanced immunoturbidimetry, or wet immunoassay. This can be determined by stain blot assay.

[0015] In yet another embodiment, SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 2 Specific to one or more polypeptides consisting of (or including) 5, 26, or 27 An isolated antibody that binds to the antibody is provided. The isolated antibody may be lyophilized and is conjugated to a label. or may be immobilized on a solid support, and may be a nucleic acid sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, , 9, 10, 11, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 2 Specific to one or more polypeptides consisting of (or including) 5, 26, or 27 The nucleic acid sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 16, 17, 18, 19, 20, 21, 22, 23 , 24, 25, 26, or 27. It may be specifically bound to

[0016] In one embodiment, the antibody may be immobilized on a solid support and may be associated with one or more labels. It may be bonded.

[0017] In yet another embodiment, the present invention relates to a method for treating acute kidney injury or active kidney disease in patients with renal disease, chronic kidney disease, or chronic renal disease. Renal impairment, active renal impairment, progressive chronic kidney disease, acute kidney injury, upper urinary tract infection, or periodontal disease A kit for diagnosing a disease comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 , 21, 22, 23, 24, 25, 26, or 27 (including or including) One or more antibodies that specifically bind to the above polypeptides, and the one or more antibodies are of interest. one or more reagents that promote binding to cystatin B polypeptides present in a sample It can include.

[0018] In another embodiment, SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 , 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27. The polypeptide may be lyophilized, conjugated to a label, or immobilized on a solid support. SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 2 6, or 27. The antibody may be specifically bound to one or more antibodies that bind to the antibody.

[0019] In yet another embodiment, the present invention relates to a method for treating renal disease in a mammalian subject, such as a human, canine, or feline subject. In one embodiment, a method for diagnosing a cancer is provided, the method comprising: (a) collecting a sample (e.g., urine, blood, plasma, plasma, etc.) from a patient having a cancer; (b) determining the amount of cystatin B polypeptide in the sample (supernatant, cells, tissue); and and comparing the amount of cystatin B polypeptide in the test sample to a control sample or a control standard. The cystatin B polypeptide level in the sample is higher than that in the control sample or control standard. The amount of Cystatin B polypeptide is indicative of a disease. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 1 7, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 (or The method includes the steps of: determining whether or not a polypeptide of the present invention is a polypeptide sequence of the present invention; Renal disease in mammals can include, for example, acute kidney injury in patients with chronic kidney disease. or active renal impairment, chronic renal disease, progressive chronic renal disease, acute renal injury, active renal impairment, In one embodiment, the kidney disease may be a cancer. It's not kidney cancer.

[0020] In one embodiment, the immunoconjugate comprises: (i) SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27. and (ii) one or more isolated antibodies that specifically bind to the one or more isolated antibodies. The immunoconjugates include one or more polypeptides. For example, SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, An immune complex is a complex formed between an antigen (e.g., a polypeptide) and an antibody. The immune complex may be immobilized on a solid support.

[0021] From the following more detailed description of certain preferred embodiments and the claims, Various embodiments will become apparent. [Brief description of the drawings]

[0022] [Figure 1] FIG. 1 shows normal tubular epithelium, cell destruction, and cell death in epithelial cells of the proximal tubule. [Diagram 2] FIG. 2 shows a Western blot analysis of cystatin B in the presence of cystatin C protein. [Diagram 3] FIG. 3 shows the standard curve obtained in the Cys B ELISA assay using native canine cystatin B (MDCK lysate). [Figure 4] FIG. 4 shows Cys B ELISA analysis of serum and urine from the canine gentamicin model. [Diagram 5] FIG. 5 shows Cys B ELISA analysis of urine from dogs presented to the clinic with inflammation or ischemia-induced active renal damage. [Figure 6] FIG. 6 shows in panels A and B reference ranges for dogs and cats. [Figure 7] FIG. 7 shows, in panels A and B, that urinary and serum cystatin B levels were significantly increased in patients diagnosed with AKI compared to healthy dogs and CKD patients. [Figure 8] FIG. 8 shows cystatin B levels in healthy animals and animals with lower urinary tract infections. [Figure 9] FIG. 9 shows detection of Cys B polypeptide in canine AKI samples, human CKD samples, and canine negative control samples. [Figure 10] Figure 10 shows Cys B levels in serum from healthy dogs. These and other objects and features will become more fully understood from the following detailed description taken in conjunction with the drawings. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] The present invention will be described in more detail below, but the examples given herein are given by way of illustration only. It is intended only that the present invention be practiced in accordance with the principles of the present invention as many modifications and variations will be apparent to those skilled in the art. As used throughout this description and the following claims, "a (one) "One of," "an," and "the" are used interchangeably depending on the context. Unless expressly stated otherwise by the FDA, the term "about" used with a numerical value includes plural referents. The term means that the value can vary by 5% above or below. For example, a value of about 100 is 95- 105 (i.e., any value between 95 and 105).

[0024] Generally, the terms used herein are used within the context of the compositions and methods described herein. Each term has its ordinary meaning in the art in the specific context in which it is used. The terminology of the section is set forth below to provide additional guidance to the practitioner regarding the description of compositions and methods. It is defined more specifically below.

[0025] The compositions and methods described herein are useful in treating a number of diseases and conditions (e.g., kidney disease, chronic Acute kidney injury or active kidney failure in patients with renal disease, progressive chronic kidney disease, acute kidney injury, active Prediction, diagnosis, and treatment of chronic kidney disease (including chronic kidney disease, active kidney disease, upper urinary tract infections, and periodontal disease) It can be used to monitor the progression of renal disease. (2) any disease that results in a decrease in the amount of blood in the kidney, or (3) physical damage to the kidney, or both. In one embodiment, renal disease does not include cancer, and does not include renal cancer. Cancer markers, including those for renal cancer, are used to assess acute kidney injury or kidney function in patients with chronic kidney disease. chronic kidney disease, progressive chronic kidney disease, active kidney injury, acute kidney injury, upper urinary tract infection or a marker for periodontal disease. Renal impairment, progressive chronic kidney disease, active renal impairment, acute kidney injury, upper urinary tract infection, or periodontal disease The diseases do not include cancer, including kidney cancer.

[0026] Chronic kidney disease (CKD) is a condition characterized by the gradual loss of kidney function over time. CKD is a chronic renal disease. CDKs are also known to be involved in kidney cancer, renal cell carcinoma, bladder cancer, and other cancers. As CKD worsens, waste products build up in the blood, causing high blood pressure, Anemia, weakened bones, malnutrition, and nerve damage can result. CKD is a cardiovascular disease. The causes of CKD include diabetes, high blood pressure, and kidney disease. , and other abnormalities. Early detection and treatment can often prevent the disease from worsening.

[0027] By the International Renal Interest Society The stages of CKD established in dogs are shown in Table 1.

[0028] [Table 1]

[0029] [Table 2]

[0030] Renal disease in humans is staged according to the glomerular filtration rate (GFR). Calculate GFR using the formula below using age, race, sex, and serum creatinine. The five stages of CKD and GFR for each stage are shown below.

[0031] Stage 1: Normal or high GFR (GFR>90mL / min) Stage 2 Mild CKD (GFR=60-89mL / min) Stage 3A Moderate CKD (GFR=45-59mL / min) Stage 3B Moderate CKD (GFR=30-44mL / min) Stage 4 Severe CKD (GFR=15-29mL / min) Stage 5 End-stage CKD (GFR<15mL / min) The methods described herein are directed to treating stage 1, 2, 3A, 3B, 4, or 5 CKD in humans. In one embodiment, the method can detect acute kidney injury or active kidney injury in a patient with kidney disease. The method is to determine whether the creatinine assay or GFR value is in stages 1, 2, 3A, 3B, 4, or The 5 stages of CKD can be detected before acute kidney injury or active kidney damage can be detected in humans. Acute kidney injury or active kidney damage in CKD stages 1, 2, 3A, 3B, 4, or 5 can be detected.

[0032] Chronic kidney disease or renal disease ase) can be either a glomerular or tubular disease.

[0033] Acute kidney injury (AKI) is defined as a sudden or rapid decrease in the kidney's filtration function. AKI can be caused by chronic kidney disease (CKD), kidney failure requiring dialysis (end-stage renal disease), or kidney disease. Mild AKI or complete recovery from AKI may not be associated with any AKI can have short-term and long-term health problems. Damage to kidney tissue due to reduced blood flow to the kidneys due to hypotension, dehydration, and exposure to substances harmful to the kidneys exposure to inflammatory processes in the kidney, systemic diseases, crush injuries, antibiotics, sepsis, or ureteral AKI can be caused by metabolic acidosis, high potassium levels, uremia, This can lead to changes in fluid balance and effects on other organ systems. I does not include cancer, including kidney cancer. International Rena AKI in cats and dogs established by the International Interest Society The grades are shown in Table 3.

[0034] [Table 3]

[0035] In one embodiment, the methods described herein are directed to treating grade 1, 2, 3, 4, or 5 AK. In one embodiment, the methods described herein can detect creatinine adenosine I. Grades 1, 2, 3, 4, or 5 AKI can be detected before the assay can detect grades 1, 2, 3, 4, or 5 AKI. , 3, 4, or 5 AKI can be detected.

[0036] AKI in humans can be staged as follows: [Table 4]

[0037] In one embodiment, the method includes detecting stage 1, 2, or 3 AKI in a human. In one embodiment, the method comprises: Before grade 1, 2, or 3 AKI can be detected in humans, It is possible to detect AKI in patients with AKI.

[0038] In one embodiment, the cause of the kidney disease, CKD, or AKI is a bacterial infection. So, what causes bacterial infections? Anaplasma species, Ehrlichia species, Leptospira species, Escherichia species, A species or Borrelia species.

[0039] Active renal impairment is defined as ongoing or progressive renal damage, renal abnormality, or renal pathology. Active renal injury results in cumulative damage to the kidney.

[0040] Polypeptides Cystatins A and B are family 1 members of the cystatin superfamily. These proteins are relatively small, measuring 11 kDa in size. The proteins are monomeric and approximately 11 kDa in size. They are not glycosylated and It does not have the disulfide bridges found in other members of the cystatin superfamily. They also lack null sequences and are therefore generally intracellular proteins restricted to certain cells. Chieng and Chaudhuri, J Health Care Poor Und erserved 2010, 21(1 sup):51. B is present in extracellular fluid and was purified from human urine. See, e.g., N et al., J Biol Chem 1986, 261:11282-11289. Statin B is a member of the cathepsin family of lysosomal cysteine ​​proteinases. , specifically, has been shown to inhibit cathepsins B, H, and L. Green et al. Biochem J 1984 218:939;D'Amico et al., J Transl. Med 2014, 12:350; Jarvinen and Rinne, Biochim See Biophys Acta 1982, 708:210-217.

[0041] Cystatin B polypeptides are described in detail in Example 1 and include the following: Included: QVKAQLEERENKKYTTFKAVTFRSQVVAGTPYFIKVQVDD DEFVHLRVFQSLPHENKPLALSSYQTNKAKHDELAYF (array Number 1) MMCGAPSASQPATADTQAIAD (SEQ ID NO: 2) MMCGAPSASQPATADTQAIADQVKAQLEERENKKYTTFKA VTFRSQVVAGTXYFIKVQVDDDEFVHLRVFQSLPHENKPL ALSSYQTNKAKHDELAYF (SEQ ID NO: 3) (where X is any amino acid) or X can be P or N) QTNKAKHDELAYF (SEQ ID NO: 4) Cystatin BC terminal "peptide 9" CGAPSASQPATADTQAIA (SEQ ID NO: 5) Cystatin B N-terminal "peptide 3-20" CGAPSASQ (SEQ ID NO: 6) Cystatin B N-terminus "peptide 3-10" CAIADQVKA (SEQ ID NO: 7) Cystatin B N-terminus "peptide 18-25" FQSLPHENKPLALSS (SEQ ID NO: 8) Cystatin B "peptide 2" SQVVAGTPYFIKVQVDDD (SEQ ID NO: 9) Cystatin B "Peptide 1" KHDELAYF (SEQ ID NO: 10) MMCGAPSASQPATADTQAIADQVKAQLEE (SEQ ID NO: 11) AIADQVKA (SEQ ID NO: 12) SQVVAGTNYFIKVQVDDD (SEQ ID NO: 13)

[0042] In one embodiment, a purified polypeptide comprising SEQ ID NO: 1-27 or a fragment thereof is provided. The polypeptide fragments of SEQ ID NOs: 1-27 are provided in the range of about 95, 90, 80, 70, 60, 50, 40, 35, 30, 25, 20, 15, 10 (or any value between about 10 and about 95 In one embodiment, the polypeptide fragment may consist of less than 10 contiguous amino acids. About 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, In one embodiment, the polypeptide comprises more than 80, 90, or 95 consecutive amino acids. The tide or fragment thereof is non-naturally occurring.

[0043] SEQ ID NOs: 1-2, 4-13, and 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 polypeptides from the full-length Cys B polypeptide The fact that small polypeptides are also small molecules is important because small polypeptides are not as large as full-length polypeptides. This is because they may have higher specificity and / or sensitivity than peptide assays. Small polypeptides of this type may be less expensive to produce, and full-length polypeptides Furthermore, the low molecular weight fragments and the low molecular weight fragments present in the sample can be obtained with a higher purity than that of the low molecular weight fragments. The level can be indicative of a disease state. Fragmented polypeptides (i.e., less than full length) Increased levels of can be a marker for disease.

[0044] A polypeptide is a polymer of three or more amino acids covalently linked by amide bonds. A purified polypeptide is one that has been purified from cellular material, other Polypeptides of the type, chemical precursors, chemicals used in the synthesis of polypeptides, or A preparation of a polypeptide that is substantially free of cellular material, culture medium, chemical precursors, or any combination thereof. A polypeptide preparation that is substantially free of substances, chemicals used in polypeptide synthesis, is about Less than 30%, 20%, 10%, 5%, 1% or more of other polypeptides, media, chemicals They contain chemical precursors and / or other chemicals used in their synthesis. The purity of the polypeptide may be about 70%, 80%, 90%, 95%, 99% or more. do.

[0045] The term "polypeptide" refers to a type of polypeptide (e.g., A "polypeptide" can refer to one or more of two or more distinct A mixture of different types of polypeptides (i.e., including but not limited to full length polypeptides) a mixture of polypeptides including a polypeptide, a truncated polypeptide, or a polypeptide fragment thereof The term "polypeptide" or "polypeptides" can refer to any of the following: The terms can also each refer to "one or more polypeptides."

[0046] A polypeptide variant or a polypeptide set forth in SEQ ID NO: 1-27 or For example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amplicons may be used for a fragment. The amino acid residues that differ are amino acid additions, substitutions, or deletions. If necessary, the sequences are aligned for maximum homology. It may occur at any position of the peptide.

[0047] Generally, variant polypeptides include modifications of one of the polypeptide sequences described herein. and evaluating the modified polypeptide to determine whether it is a biological equivalent. The biological equivalent of the variants can be confirmed by immunohistochemical assays. , enzyme-linked immunosorbent assay (ELISA), immunoturbidimetry, particle-enhanced immunoturbidimetry, radioimmunology In assays such as radioimmunoassays (RIA) or Western blot assays, If the polypeptide reacts substantially the same as the polypeptide described in the document, e.g., 90% of the original polypeptide, In one embodiment, the assay is performed in a biologically equivalent manner. A polypeptide having a high affinity for a given antigen or antibody is a polypeptide described herein. It is a competitive assay that can reduce the Antibodies that specifically bind to the target polypeptide also specifically bind to the variant polypeptide. do.

[0048] Variant polypeptides have at least one amino acid sequence similar to that of the polypeptides set forth in SEQ ID NOs: 1-27. Approximately 80% or approximately 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 , 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical. For example, The variant polypeptides of SEQ ID NOs: 1-27 have at least Approximately 99.5%, 99%, 98%, 97%, 96%, 95%, 94%, 90%, 87%, 8 A variant polypeptide may have one or more conservative amino acids identical to the amino acid sequence of the target polypeptide. , which have acid variations or other minor modifications while retaining biological activity, i.e. Biologically functional equivalents to SEQ ID NOs: 1-27. Biologically active equivalents has substantially equivalent functions to the corresponding polypeptide.

[0049] Methods for introducing mutations into amino acid sequences are well known to those skilled in the art. L (ed.), Current Protocols in Molecular Biol. ogy, John Wiley and Sons, Inc. (1994);Mania tis et al., Molecular Cloning: A Laboratory Manu al, Cold Spring Harbor laboratory, Cold Sp See QuickCell Harbor, NY (1989). Commercially available mutagenesis kits such as the "hange™ Site-Directed Mutagenesis Kit" (Stratagene) are available. A kit can also be used to introduce the functionally active variant polypeptide. The peptide is produced by replacing amino acids that do not affect the function of the polypeptide. It can be achieved.

[0050] The variant polypeptides may have a conserved sequence at one or more predicted non-essential amino acid residues. Conservative substitutions are those that are understood by those skilled in the art of peptide chemistry to be A shape that would predict that the secondary structure and hydropathic properties of the polypeptide would be substantially unchanged. is the replacement of one amino acid with another that has similar properties. Groups of amino acids correspond to conservative changes: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr;(2)cys, ser, tyr, thr;( 3) val, ile, leu, met, ala, phe; (4) lys, arg, his and (5) phe, tyr, trp, his. In one embodiment, the polypeptide has about , 2, 3, 4, 5, 10, 20, or fewer conservative amino acid substitutions.

[0051] As used herein, the percent identity of two amino acid sequences (or two nucleic acid sequences) The algorithm of Karlin and Altschul (PNAS USA 87:22 64-2268, 1990) as revised by Karlin and Altschul (PN AS USA 90:5873-5877, 1993) is used to determine the The algorithm was that of Altschul et al. (J. Mol. Biol. 215:403-410, BLAST is incorporated into the NBLAST and XBLAST programs of the BLAST Library (1990). Nucleotide searches were performed using the NBLAST program with score=100 and word Length=12. BLAST protein searches were performed using the XBLAST program. For comparison, the score is set to 50 and the word length is set to 3. To obtain a matched alignment, use Altschul et al. (Nucleic Acids Re s.25:3389-3402, 1997) using GappedBLAST. When using BLAST or GappedBLAST, please use the respective programs. The default parameters for the BLAST and NBLAST programs are as set forth herein. Used to obtain nucleotide sequences homologous to the described nucleic acid molecules.

[0052] Identity or identical refers to the similarity of amino acid sequences, and these terms are used in the art. Sequences that share the same or similar amino acids have the meaning recognized by the US Pat. Sequence identity refers to the percentage of amino acids that are identical to the native amino acid sequence of the antibody. The sequences are aligned and gaps are inserted, if necessary, to maximize sequence identity. Therefore, the amino acid sequence that shares 85% amino acid sequence identity with the reference sequence is A candidate sequence having the above structure is one in which, after alignment of the candidate sequence with the reference sequence, 85% of the amino acids in the candidate sequence have the following structure: Identical to the corresponding amino acid in the reference sequence and / or constitute conservative amino acid changes It is necessary.

[0053] A polypeptide or antibody is a molecule that is covalently linked to an amino acid sequence that is not normally associated with it. Additionally, the polypeptide or antibody may be linked to a non-amino acid residue or non-covalently. It may be covalently or non-covalently attached to a compound or molecule, for example a polypeptide or The antibody or antibody may contain an indicator reagent, an amino acid spacer, an amino acid linker, a signal sequence, a transporter, Whether bound to a stop sequence, a transmembrane domain, a protein-purified ligand, or a combination thereof In one embodiment, the protein purification ligand may be, for example, or one or more C amino acid residues at the carboxy terminus. is a sequence of amino acids not normally associated with any polypeptide or antibody The amino acid spacer can be about 1, 5, 10, 20, 100, or 1,000 amino acids. It can include.

[0054] The polypeptide further comprises a signal that directs the transport of the protein co- or post-translationally. The polypeptide may include a null (or leader) sequence. to facilitate synthesis, purification, or identification of the Inclusion of a linker or other sequence to enhance binding of the polypeptide to the solid support. For example, the polypeptide may be a polypeptide that is ... It may be bound to the

[0055] A polypeptide is a sequence of amino acids that is not normally related in any way, i.e., a heterologous amino acid. A heterologous amino acid sequence may be covalently or non-covalently linked to the amino acid sequence. These sequences may be any of a variety of sequences, even synthetic sequences, usually extending to the carboxy terminus of a polypeptide. Furthermore, a polypeptide may be a sequence that is not located at the amino terminus. The antibody may be covalently or non-covalently bound to another compound or molecule, such as an indicator reagent. The peptide may include an amino acid spacer, an amino acid linker, a signal sequence, a stop transfer sequence, Covalently or non-covalently linked to a transmembrane domain, a protein purification ligand, or a combination thereof The polypeptide may also be combined with a moiety that enhances the immune response (i.e., a functional group which may be a peptide or other compound (e.g., a cytokine such as IL-2); Moieties that facilitate purification (e.g., 6-histidine tag, trpE, glutathione maltose affinity tags, such as binding proteins, or moieties that promote the stability of the polypeptide Molecular weight (e.g., polyethylene glycol; acetyl, propyl, succinyl, benzyl, amino terminus protecting groups such as benzyloxycarbonyl, or t-butyloxycarbonyl; amide, methylamide, and ethylamide) In one embodiment, the protein purification ligand may be, for example, at the amino terminus of the polypeptide. or one or more C amino acid residues at the carboxy terminus or at both termini. An amino acid spacer is a sequence of amino acids that is not associated with any polypeptide. The amino acid spacer can be about 1, 5, 10, 20, 100, or 1,000 amino acids. It can include.

[0056] If desired, the polypeptide may further include other amino acid sequences, such as amino acid linkers, amino acid Spacer, signal sequence, TMR stop sequence, transmembrane domain, and protein purification Ligands useful for the production of, e.g., glutathione-S-transferase, histidine tags and Staphylococcal protein A, or a combination thereof. A fusion protein is a protein that contains two or more different amino acid sequences operably linked together. The fusion protein constructs are synthesized by synthesising the individual polypeptides using organic synthesis techniques. It can be chemically synthesized by linking peptide fragments together into a fixed sequence. The fusion protein construct also contains a sequence encoding amino acid residues in the correct sequence. The in vitro cultured cells carry an expression vector having a recombinant DNA sequence determined by the method. Alternatively, the heterologous polypeptide can be expressed by a genetically modified host cell (e.g., E. coli) cultured in a manner similar to that described above. The polypeptide may be fused, for example, to the N-terminus or C-terminus of the polypeptide. There may be more than one polypeptide in a fusion protein. The fusion protein may comprise, for example, a sequence represented by SEQ ID NO: 1-27, a fragment thereof, or The polypeptide may include one or more of the following: That is, the polypeptide can contain two or more copies of SEQ ID NOs: 1-27 or It may include combinations thereof.

[0057] In one embodiment, the polypeptide is from a human, rabbit, mouse, dog, cat, other mammal, or a combination thereof. The polypeptide may be purified using standard protein purification techniques. The polypeptides can be isolated from cells or tissue sources. Polypeptides can also be synthesized or produced chemically by techniques. The peptide can be synthesized using a peptide synthesizer of the type.

[0058] In one embodiment, the polypeptide is attached, covalently or non-covalently, to a solid phase or substrate. Cohesively fix.

[0059] The polypeptide may be recombinantly produced. The recombinant gene can be expressed in a suitable expression host system using techniques well known in the art. A variety of bacterial, yeast, mammalian, and insect expression systems are known in the art. Any such expression system available in the art can be used. Thus, the polynucleotide encoding the polypeptide is translated into a cell-free translation system. The polypeptide may be lyophilized, powdered, or dried, e.g., free It can also be dried.

[0060] Polynucleotides In one embodiment, an isolated polypeptide encoding one or more of the polypeptides disclosed herein is provided. The polynucleotides of the present invention include those that contain less than an entire genome and are Polynucleotides can be single-stranded or double-stranded nucleic acids. It can be human DNA, chemically synthesized RNA or DNA, or a combination thereof. Polynucleotides can be synthesized by combining them with other components, such as proteins, lipids, and other polynucleotides. For example, the polynucleotides can be purified to be free of 50%, 75%, 90%, %, 95%, 96%, 97%, 98%, 99%, or 100% purified. In one embodiment of the invention, the polynucleotide is a polypeptide shown in SEQ ID NO: 1-27. The nucleic acid sequence encoding the nucleic acid sequence of the present invention is

[0061] The polynucleotides of the invention may contain other nucleotide sequences, e.g. sequences encoding linkers. Useful for sequences, signal sequences, TMR stop transport sequences, transmembrane domains, or protein purification Suitable ligands include, for example, glutathione-S-transferase, histidine tags, and It may contain staphylococcal protein A.

[0062] The polynucleotides of the present invention can be isolated. An isolated polynucleotide is one that is naturally occurring. is not immediately adjacent to one or both of the associated 5' and 3' flanking genomic sequences; An isolated polynucleotide is, for example, a polynucleotide of any length. However, the recombinant D The nucleic acid sequences found in nature immediately adjacent to the NA molecule are removed or absent. An isolated polynucleotide also includes non-naturally occurring nucleic acid molecules.

[0063] Degenerate nucleotide sequences encoding the polypeptides of the invention are also contemplated as polynucleotides of the invention. A degenerate nucleotide sequence is one that encodes a polypeptide of the invention or a fragment thereof. polynucleotide, but due to the degeneracy of the genetic code, it is possible to distinguish between the wild-type polynucleotide sequence and The polynucleotides of the invention that encode physiologically functional polypeptides differ in their nucleic acid sequences. Complementary DNA (cDNA) molecules, species homologs, and variants of the nucleotides are also included in the polynucleotides of the present invention. It is leotide.

[0064] The polynucleotides of the invention may comprise a coding sequence for a naturally occurring polypeptide. Alternatively, the polypeptide may encode modified sequences that are not naturally occurring. The nucleotides may be any expression control element (e.g., replication origin, promoter, enhancer, or or other control elements that drive expression of the polynucleotide of the present invention in a host cell. The expression vector can be, for example, pBR 322, pUC, or ColE1 plasmids, or adenovirus type 2 vectors. The vector may be an adenovirus vector, such as a type 5 vector or a type 6 vector. Other vectors may also be used, including but not limited to, SIRT1, SIRT2, and SIRT3. Indovirus, Simian virus 40, Alphavirus vector, Poxvirus viral vectors, as well as cytomegalovirus and retroviral vectors (e.g., mouse Sarcoma virus, Mouse mammary tumor virus, Moloney murine leukemia virus, and Routine sarcoma virus. Also included are minichromosomes (e.g., MC and MC1), bacteriophages (e.g., sarcoma viruses), Phage, phagemid, yeast artificial chromosome, bacterial artificial chromosome, virus particle, virus plasmids (plasmids with the cos site of phage lambda inserted), and Precons (genetic elements capable of replicating within a cell under their own control) can also be used.

[0065] Preparing a polynucleotide operably linked to an expression control sequence and expressing it in a host cell Methods are well known in the art. See, e.g., U.S. Pat. No. 4,366,246. The polynucleotides of the invention may be used to direct the transcription and / or translation of the polynucleotide. Operatively linked when located adjacent to or near one or more expression control elements There are.

[0066] The polynucleotides of the present invention can be used, for example, as probes or primers (e.g., PCR primers). primers) to detect the presence of polynucleotides in a test sample (e.g., a biological sample). A probe is a molecule capable of detecting the presence of a target gene, typically in a sequence-specific manner, e.g. A molecule capable of interacting with a target nucleic acid through hybridization. Primer refers to a nucleic acid that is capable of supporting enzymatic manipulation and that hybridizes with a target nucleic acid so that the enzymatic manipulation occurs. A primer is a subset of a probe that can be hybridized to a nucleotide sequence. nucleotide or nucleotide derivatives, or similar available in the art that do not interfere with the enzymatic manipulation. The peptide may be made from any combination of analogs.

[0067] The probe or primer may be selected from about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 3 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 4 0, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, or It may be more than one consecutive nucleotide.

[0068] antibody The antibodies include those comprising the cystatin B polypeptides described herein, the variant cystatin B polypeptides described herein, Antibodies that specifically bind to a statin B polypeptide, or a fragment thereof, are included. An antibody is capable of specifically binding to multiple polypeptides. Also included are intact antibodies, or antigen-binding portions thereof that compete with intact antibodies for antigen binding. The term "antibody" also refers to one or more cystatin B polypeptides or fragments thereof. Any type of antibody molecule or specific Antibodies include naturally occurring, non-naturally occurring, synthetic binding molecules. As used herein, the "antigen-binding portion" of an antibody may be a polypeptide that is genetically engineered or genetically engineered. The terms "antigen-binding fragment" of an antibody, "antigen-binding fragment" of an antibody, and the like refer to a cystatin B polypeptide (e.g., A naturally occurring, enzymatically isolated antibody that specifically binds to and forms a complex with the target nucleic acid sequence (SEQ ID NO: 1-27). Any obtainable, synthetic, or genetically engineered polypeptide, glycoprotein, or Contains immunoglobulins.

[0069] The antibody or fragment thereof binds to an epitope of a polypeptide described herein. They can be produced in vivo in suitable laboratory animals or by recombinant DNA techniques. The means for preparing and characterizing antibodies include It is well known in the art. See, e.g., Dean, Methods Mol. Biol. 80 :23-37(1998);Dean, Methods Mol.Biol.32:36 1-79(1994); Baileg, Methods Mol.Biol.32:38 1-88(1994);Gullick, Methods Mol.Biol.32:3 89-99(1994);Drenckhahn et al. Methods Cell.Bio l.37:7-56(1993);Morrison,Ann.Rev.Immunol .10:239-65(1992);Wright et al. Crit.Rev.Immuno For example, polyclonal antibodies are described herein. The polypeptides described in administering the drug to animals (such as cats, guinea pigs, goats, pigs, dogs, cows, sheep, donkeys, or horses) Serum is collected from the immunized animal and antibodies can be generated by, for example, ammonium chloride, followed by affinity chromatography. Polyclonal antibodies are generated and purified from plasma by performing chromatographic analysis. Techniques for processing are known in the art.

[0070] Antibodies include IgG (IgG1, IgG2, IgG2a, Ig2b, IgG3, IgG4) Any isoform may be used, including IgM, IgA (IgA1 and IgA2), IgD, and IgE. It can be a type.

[0071] The antibody may be a monoclonal antibody, a polyclonal antibody, a chimeric antibody, or an antigen-binding A monoclonal antibody is a substance derived from a population of substantially homogeneous antibodies. A substantially homogenous antibody population may contain minor amounts of mutants or variants. Monoclonal antibodies are highly specific and interact with a single antigenic site. Monoclonal antibodies typically target a single epitope, whereas polyclonal antibodies A population of monoclonal antibodies typically contains a variety of antibodies that target a diverse set of epitopes. Clonal antibodies can be produced, for example, by the hybridoma method (Kohler and Milstein, N ature 256:495, 1975), recombinant methods (U.S. Pat. No. 4,816,567 ), and isolation from a phage antibody library (Clackson et al., Nature 3 52:624-628, 1991; Marks et al., J. Mol. Biol. 222:58 It can be produced by a number of methods, including those described herein (1991, 1-597).

[0072] Chimeric antibodies or antigen-binding portions thereof may be directed to a particular species or a particular class or subclass of antibodies. have a portion of the heavy and / or light chains derived from a different species, are from different antibody classes or subclasses. For example, n,Science 229:1202(1985);Oi et al., BioTechniqu es 4:214(1986);Gillies et al., J.Immunol.Method s 125:191-202 (1989); U.S. Patent No. 5,807,715; U.S. Patent No. 4, See No. 816,567; No. 4,816,397.

[0073] Chimeric antibodies can be produced, for example, by CDR grafting (EP 239,400; PCT Publication WO 2004 / 023363). 91 / 09967; U.S. Patent Nos. 5,225,539; 5,530,101; and No. 5,585,089), veneering or resurfacing Resufacing (EP592,106; EP519,596; Padl an, Molecular Immunology 28:489-498(1991) ;Studnicka et al., Protein Engineering 7(6):805 -814(1994);Roguska et al., PNAS 96:969-973(1994) ) and chain shuffling (U.S. Patent No. 5,565,332). It can be generated using

[0074] In one embodiment, a chimeric antibody may comprise variable and constant regions of different species. For example, an antibody can be produced by combining heavy and light chain variable regions from one mammal with those from a different animal (e.g., The constant regions of the heavy and light chains of the human (mouse, rabbit, dog, cat, or human) may be included. Chimeric antibodies are characterized in that neither the CDR nor the framework sequences are introduced into the recipient antibody. It can contain additional amino acids that are not included in the formula. Such amino acids are introduced to better optimize the ability of antibodies to recognize and bind antigens. For example, amino acids in the framework regions of the variable regions of an antibody can be modified as needed. The CDRs of the reshaped antibody can be replaced to form a suitable antigen-binding site. Yes. See Sato et al., Cancer Res. (1993) 53:851-856. .

[0075] Non-limiting examples of antigen-binding portions or fragments of antibodies include the following: Fab fragment; Fab' fragment; Fab'-SH fragment; F(ab')2 fragment; Fd fragment; Fv fragments; single-chain Fv (scFv) molecules; sdAb fragments (nanobodies); Fab-like antibodies ( Contains the heavy and light chain variable regions equivalent to the Fab fragment obtained by papain digestion Antigen-binding fragment; F(ab')2-like antibody (F(ab')2 obtained by pepsin digestion) (Antigen-binding fragment containing two antigen-binding domains equivalent to the antigen-binding fragment prepared from the antigen fragment) Multispecific antibodies, diabodies, bispecific antibodies, multifunctional antibodies, humanized antibodies, caninized antibodies Antibody, human antibody, dog antibody, cat antibody, mouse antibody, rabbit antibody, synthetic antibody, CDR graph and a minimal recognition unit consisting of amino acid residues that mimic the hypervariable region of an antibody (e.g. , an isolated complementarity determining region (CDR) such as a CDR3 peptide, or a restricted FR3-CDR 3-FR4 peptide. Also, other engineered molecules, such as domain-specific antibodies, Single domain antibodies, domain deleted antibodies, CDR graft antibodies, diabodies, tribodies , tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, di), single chain (Fv)2 (sc(Fv)2); bivalent (scFv)2); tetravalent ([sc( Fv)2]2) scFv antibodies, small modular immunopharmaceuticals (SMIPs), and Variable IgNAR domains are also considered "antigen-binding fragments or portions" herein. do. "Specifically binds" "specifically bind" or "specific to" refers to a first antigen For example, the polypeptides of SEQ ID NOs: 1-27 have a higher affinity than other non-specific molecules. The term "specific binding" refers to a molecule that recognizes and binds to an antibody described herein. "specifically binds" or "specifically binds" "cally bind" or "specific for" refers to a first antibody, e.g., SEQ ID NO:1 The antibodies raised against -27 bind to SEQ ID NO: 1 with higher affinity than other non-specific molecules. It also means that the non-specific molecule recognizes and binds to the first antigen. Specific binding is, for example, by enzyme-linked immunosorbent assay (ELISA). ISA), radioimmunoassay (RIA), immunoturbidimetry, particle-enhanced immunoturbidimetry, or Wes This can be tested using a tandem blot assay, using methodologies well known in the art. do.

[0076] In one embodiment, the antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 2 1, 22, 23, 24, 25, 26, 27, or 27 In one embodiment, the epitope specifically binds to the AYFLAYF (SEQ ID NO: 20), ELAYF (SEQ ID NO: 21), DELAYF (SEQ ID NO: 22), HDELAYF (SEQ ID NO: 23), KHDELAYF (SEQ ID NO: 10), AKHDELAYF (SEQ ID NO: 24), KAKHDELAYF (SEQ ID NO: 25), NKAKHDELAYF (SEQ ID NO: 2 6), TNKAKHDELAYF (SEQ ID NO: 27), or QTNKAKHDELAYF (Sequence number 4).

[0077] In one embodiment, the antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NOs: 1-27 or fragments thereof. The antibody competes with a second or reference antibody for binding to the antibody. Any competitive binding assay can be used. can be used to measure competition between two antibodies against the same antigen. A cross-reactivity assay such as a cross-ELISA assay can be used for this purpose. Means for this are well known to those of skill in the art (see, for example, Dowbenko et al. (1988) J. Virol. .62:4703-4711).

[0078] Using any assay used to assess competitive binding, the first antibody is detected in the presence of the first antibody. The binding of the antibody to the antigen is at least about 30%, 40%, 50%, 60%, 75%, If the binding is reduced by 90% or more, the first antibody competitively inhibits the binding of the second antibody. It is thought that this is the case.

[0079] Competitive binding may involve binding to one or more isolated polypeptides set forth in SEQ ID NOs: 1-27 attached to a solid support. and determining the ability of the antibody to bind to or associate with the polypeptide. by assaying the ability of the antibody to compete with the antibodies described herein for binding to It is possible.

[0080] The antibody includes: (a) a reference antigen in binding to SEQ ID NO: 1-27, or an antigen-binding fragment thereof; (b) antibodies and antigen-binding fragments thereof that compete with the reference antibody; (c) an antibody that binds to an epitope of the antigen-binding fragment thereof and an antigen-binding fragment thereof; Virtually the same K d and antibodies that bind to SEQ ID NO: 1-27 or antigen-binding fragments thereof and / or (d) a binding fragment of SEQ ID NO:1- with substantially the same off-rate as the reference antibody. 27 or an antigen-binding fragment thereof, wherein the reference The reference antibody is 7 Binding affinity K of l / mol or higher a SEQ ID NO:1- Antibodies that specifically bind to the polypeptides or antigen-binding fragments thereof of 27 or antigen-binding fragments thereof It is a fragment.

[0081] Affinity of an antibody or antigen-binding fragment thereof for a polypeptide partner can be expressed by the dissociation constant (Kd). The equilibrium dissociation constant (Kd) is k off / k onChen, Y. et al., 1999, J. Mol. Biol. 29 3:865-881. Various methods for measuring affinity constants are known in the art. In certain embodiments, the reference antibody has a particular K on Rate / Meeting Rate or K off The polypeptides of SEQ ID NOs: 1-27 have a binding affinity at a rate of In one embodiment, the antibody is an antibody or antigen-binding fragment thereof that binds to 6×10 5 M -1 s - 1 or better on The antibody specifically binds at 5 × 10 -6 s -1 or it Better K off Alternatively, the antibody may be 500 pM, 400 pM, 300pM, 200pM, 100pM, 50pM, 40pM, 30pM, 20pM, and specifically binds with better binding affinity.

[0082] Antibodies that specifically bind to SEQ ID NOs: 1-27 can be isolated from samples (e.g., serum, blood, in plasma, cells, tissues, saliva, plaque, gingival crevicular fluid, gingival biopsy, tongue swab, or urine sample) The present invention is particularly useful for detecting the presence of cystatin B polypeptides and fragments thereof present in Immunoassays can utilize one antibody or several antibodies. A typical method is, for example, the use of a monoclonal antibody specific to one epitope, a polypeptide A combination of monoclonal antibodies specific for multiple epitopes of different polypeptides. Monoclonal antibodies specific to a topic, polyclonal antibodies specific to the same antigen, different Antigen-specific polyclonal antibodies, or monoclonal and polyclonal antibodies Immunoassay protocols can be used in combination with, for example, competitive, direct reaction, These can be based on assays of the ELISA type, or of the sandwich type, e.g., using labeled antibodies. The antibody can be labeled with any type of label known in the art. Identification includes, for example, fluorescence, chemiluminescence, radioactivity, enzymes, colloidal metals, radioisotopes, and bioluminescent labels.

[0083] The antibodies or antigen-binding fragments thereof are bound to a support and are detected in samples for certain diseases and conditions. It can be used to detect the presence or amount of a polypeptide present. For example, glass, polystyrene, polypropylene, polyethylene, dextran, nylon Amylases, natural and modified celluloses, polyacrylamides, agarose, and magnesium Magletite. The antibody or antigen-binding fragment thereof may be freeze-dried. It may be dried, powdered or desiccated, for example freeze-dried.

[0084] The antibodies can further be used to isolate polypeptides by immunoaffinity columns. The antibodies may also be modified, for example by absorption or covalent coupling, so as to retain their immunoselective activity. Optionally, the accessibility of the antigen-binding site of the antibody can be improved by immobilizing the antibody on a solid support. Spacer groups can be included to ensure that the .alpha.-amino acid sequence is maintained. , biological samples (including but not limited to saliva, plaque, gingival crevicular fluid, gingival biopsy) , tongue swabs, serum, blood, and urine) It can be effectively bonded.

[0085] Antibodies can also be used in immunolocalization studies to characterize different cellular events or physiological states. The presence and distribution of the polypeptides described herein can also be assayed using antibodies. can be used to identify molecules involved in passive immunity or involved in the biosynthesis of non-protein antigens. It is also possible to identify molecules that are useful for vaccine development. Antibodies (including, for example, monoclonal antibodies and single chain antibodies) can be used to detect certain specific The progression of a particular disease or condition can be monitored by determining the sequence number of the sequence in a test sample from an animal. The aim is to improve the disorder by measuring the increase or decrease in the amount of No. 1-27 or a fragment thereof. It is possible to determine whether a particular targeted therapeutic regimen is effective. For example, direct binding assays such as RIA, ELISA, or Western blot assays can be used to detect and / or quantitate.

[0086] Methods of detection In one embodiment, a method for detecting a cystatin B polypeptide in a sample comprises the steps of: One or more antibodies specific for SEQ ID NOs: 1-27 are combined with a cystatin B polypeptide and SEQ ID NOs: and contacting the antibody with one or more antibodies specific for 1-27 under conditions suitable for the formation of a complex. Methods are provided that include combining a cystatin B polypeptide with one or more polypeptides specific for SEQ ID NOs: 1-27. Complexes with the above antibodies are detected.

[0087] In one embodiment, the method for detecting polypeptides comprising SEQ ID NOs: 1-27 and fragments thereof comprises: Optionally, the amount of a polypeptide comprising SEQ ID NO: 1-27 in a sample is detected. The relative levels of the polypeptides can be used to diagnose or treat a number of diseases or conditions. Any method for detecting a polypeptide known in the art can be used in the present invention. It can be used in the manner described in the specification.

[0088] Assay methods for use with the antibodies described herein include direct and indirect labeling techniques. , immunoaffinity columns, immunomagnetic beads, fluorescence activated cell sorting (FAC S), enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), agglutination assay Nephelometric assay, quantitative nephelometric assay, and primary antibodies A labeled secondary antibody that detects the

[0089] The antibody may be fluorescently labeled, for example, with a fluorescent label having excitation and emission wavelengths suitable for detection. The antibodies can be detectably labeled using commercially available equipment such as fluorescent cell sorters. Examples of markers include phycoerythrin (PE) and fluorescein isothiocyanate (FI). TC), Rhodamine (RH), Texas Red (TX), Cy3, Hoechst 33258, and 4'6-diamino-2-phenylindole (DAPI). Such labels can be attached to the antibody using standard techniques (Maino et al. , 1995, Cytometry 20:127-133).

[0090] The methods described herein can be used to detect SEQ ID NOs: 1-27 or fragments thereof. and wherein the antibody or antigen-binding antibody fragment specifically binds to SEQ ID NO: 1-27. Biological samples include, for example, serum, blood from animals (e.g., dogs, cats, or humans). Examples of such samples may include tissue samples, cells, plasma, saliva, plaque, gingival crevicular fluid, gingival biopsy, tongue swab, or urine. Test samples may be untreated or may have been precipitated, fractionated, separated, diluted, concentrated, or purified. stomach.

[0091] As used herein, a "patient" or "subject" refers to a human, Or it may mean a non-human animal, including a cat, cow, pig, horse, or dog.

[0092] As used herein, the terms "sample," "test sample," "patient sample," or "subject sample" The term includes, but is not limited to, blood, serum, plasma, saliva, etc. obtained from a subject. , plaque, gingival crevicular fluid, gingival biopsy, tongue swab, or urine sample.

[0093] Assays include, but are not limited to, competitive, direct reaction, or sandwich assays. These include, but are not limited to, enzyme-linked immunosorbent assays. Adsorption assay (ELISA), Western blot, IFA, radioimmunoassay (RIA), Hemagglutination (HA), immunoturbidimetry, particle-enhanced immunoturbidimetry, fluorescence polarization immunoassay (FPIA) and microtiter plate assays (one or more wells of a microtiter plate) Some assays are performed using reversible flow chromatography. Reversible flow chromatography binding assay phic binding assay, such as the SNAP® assay See, for example, U.S. Patent No. 5,726,010.

[0094] The assay may use a solid phase or substrate, or may involve immunoprecipitation or solid phase The method can be carried out by any other method that does not utilize a solid phase or substrate. In some cases, one or more of the polypeptides or antibodies may be attached to a solid support or substrate (e.g., a microplate reader). Titer wells, magnetic beads, non-magnetic beads, columns, matrices, membranes, synthetic or Natural fibers (e.g., glass or cellulose-based materials, or polyethylene, poly A fiber mat made of a thermoplastic polymer such as polypropylene or polyester. , sintered structures composed of particulate materials (e.g., glass or various thermoplastic polymers), or or nitrocellulose, nylon, polysulfone, etc. (generally synthetic in nature) In one embodiment, the substrate is a Sintered polyethylene particles, commonly known as porous polyethylene, e.g. Ch 10-15 manufactured by romex Corporation (Albuquerque, NM) All of these substrate materials are available in the form of films, sheets, or It can be used in any suitable shape such as a paper or plate, or it can be made of paper, glass, plastic, etc. coated or bonded to a suitable inert carrier such as a plastic film or fabric. Suitable methods for immobilizing antibodies on a solid phase include ionic, hydrophobic, and Examples of such interactions include molecular interactions, molecular-based interactions, and covalent interactions.

[0095] In one embodiment, the method comprises the steps of: detecting a test sample and detecting one or more antibodies that specifically bind to SEQ ID NOs: 1-27. allows the formation of polypeptide / antibody complexes, i.e. immune complexes, with multiple antibodies. That is, the antibody is contacted under conditions in which the antibody is capable of binding to the target molecule of SEQ ID NO: 1-27 located in the sample. The antibody / polypeptide complex specifically binds to one or more of the polypeptides of the present invention. The subject is familiar with the assays and conditions used to detect binding of the polypeptides in the sample. and the formation of an antibody-antibody complex is detected. The formation of an antibody / polypeptide complex indicates that the polypeptide This indicates that the peptide is present in the patient sample.

[0096] In one embodiment, an indicator reagent, such as an enzyme conjugate attached to the antibody, catalyzes a detectable reaction. If the polypeptide / antibody complex is detected, the polypeptide / antibody complex is detected. and subjecting an indicator reagent containing the compound to conditions that allow for the formation of a polypeptide / antibody / indicator complex. The polypeptide / antibody / indicator complex may be detected. Optionally, the polypeptide or antibody is ligated prior to formation of the polypeptide / antibody complex. The subject matter may be labeled with an indicator reagent. The method optionally includes positive or negative controls. The positive control is a sample containing an antibody specific for Cys B that specifically binds to the antibody and gives a positive result. A negative control may contain one or more polypeptides that are believed to affect the Any Cys B polypeptide may also be used that specifically binds to or cross-links with an antibody specific for Cys B. It does not contain any polypeptides or other components that may react.

[0097] In one embodiment, one or more antibodies are attached, either covalently or non-covalently, to a solid phase or substrate. A sample that may contain Cys B polypeptide is added to the substrate. One or more antibodies specific for Cys B are added to the substrate. The antibodies are the same as those used in the solid phase. may be the same antibody as in, or may be from a different source or species. The antibody may be conjugated to an indicator reagent, such as an enzyme conjugate. A washing step is carried out before each addition. A chromophore or enzyme substrate is added to develop color. The color reaction is stopped, e.g. Color development can be quantified, for example, using a spectrophotometer.

[0098] In another embodiment, one or more antibodies are immobilized on a solid phase or substrate. A test sample that may contain the peptide is added to the substrate. Add a second anti-species antibody that binds the opposite species This second anti-species antibody is from a different species than the antibody immobilized on the solid phase. a third antibody that specifically binds to the first anti-species antibody and does not specifically bind to the antibody immobilized on the solid phase; The species antibody is added. The third anti-species antibody can include an indicator reagent, such as an enzyme conjugate. A washing step may be performed before each addition. A chromophore or enzyme substrate is added to develop color. The color reaction is stopped and the color development can be quantified, for example, using a spectrophotometer. Cut.

[0099] In one embodiment, the one or more capture antibodies are directed to one or more of the polypeptides described herein. The capture antibody or antibodies can specifically bind to an epitope selected from the group consisting of SEQ ID NOs: 1-27. One or more of the polypeptides of the present invention can be used to immobilize, for example, a solid support. The one or more detection antibodies may target the same or different epitopes of the polypeptide. The detection antibody is capable of specifically binding to one or more of the above epitopes. This embodiment can be used to detect or visualize fixation to the body. This is more specific and sensitive than assays that use a single antibody for both capture and detection functions. This is advantageous because of its high

[0100] In one type of assay format, one or more antibodies are coated onto a solid phase or substrate. The polypeptides suspected of containing SEQ ID NO: 1-27 or fragments thereof may be A test sample containing the polypeptide is subjected to a signal generating reaction that binds to an antibody or antibody fragment specific for the polypeptide. A solid phase antibody or polypeptide directed against the test sample polypeptide is attached to the solid phase together with an indicator reagent containing a synthetic compound. conditions sufficient for the formation of an antigen / antibody complex of an indicator compound bound to a peptide-specific antibody The indicator reagent bound to the anti-polypeptide antibody is incubated for a certain period of time. Binding can be measured quantitatively. The signal generated from a control sample or control standard can be used to A measurable change in signal compared to the control indicates a polypeptide comprising SEQ ID NO: 1-27 or This type of assay is used to determine the presence of a polypeptide or fragment thereof in a test sample. The amount of tide can be quantified.

[0101] Another type of assay format involves coating one or more antibodies to a carrier or substrate. The antibody is conjugated to an indicator reagent and added to the test sample. This mixture is applied to a carrier or substrate. If Cys B polypeptide is present in the test sample, the Cys B polypeptide is Binding to one or more antibodies bound to a reagent or to one or more antibodies immobilized on a support The polypeptide / antibody / indicator complex can then be detected. Such assays can quantitate the amount of the polypeptide in a test sample.

[0102] Another type of assay format involves coating one or more antibodies to a carrier or substrate. The test sample is applied to the support or substrate and incubated. The solid support is washed with a washing solution. By washing away unbound components from the sample, If a polypeptide containing the polypeptide or a fragment thereof is present in the test sample, the polypeptide coated on the solid phase is This polypeptide / antibody complex will bind to a second antibody bound to an indicator reagent. and the polypeptide / antibody / anti-species antibody can be used to detect the This type of assay is capable of detecting the presence of a polypeptide in a test sample. The amount of peptide can be quantified.

[0103] The formation of a polypeptide / antibody complex or a polypeptide / antibody / indicator complex can be achieved, for example, by Detection may be by radiometric, colorimetric, fluorometric, size separation, or precipitation methods. Optionally, detection of the polypeptide / antibody complex can be achieved by using a signal generating compound. This is done by adding a second antibody conjugated to an indicator reagent containing An indicator reagent containing a signal generating compound (label) associated with the somatic complex can be prepared using the methods described above. These can be detected using colorants, catalysts such as enzyme conjugates, fluorescein and rhodontics. Fluorescent compounds such as dammines, dioxetanes, acridiniums, phenanthridiniums, and rutheniums. chemiluminescent compounds such as fluorescein, ... Cofactors, inhibitors, magnetic particles, etc. Examples of enzyme binding pairs include alkaline phosphatase Examples include α-amycin, horseradish peroxidase, and beta-galactosidase. The choice of a particular label is not critical, but choosing a particular label is and capable of generating a signal by itself or together with one or more further substances. It is believed that this will be possible.

[0104] As used herein, the phrase "determining the amount" refers to determining the amount of one or more polypeptides in a sample. This refers to measuring or identifying the level of a polypeptide as known in the art. This can be achieved by a methodology for detecting the presence of β-amyloides, for example, enzyme-linked immunosorbent assay (ELISA). SA), radioimmunoassay (RIA), immunoturbidimetry, particle-enhanced immunoturbidimetry, or Western blot analysis. Alternatively, the antibody may be used in combination with SEQ ID NO:1- The identity of the 27 polypeptides may be determined by mass spectrometry or similar methods known to those skilled in the art. Determining the amount of polypeptide present in a sample can be accomplished using such in vitro analysis. This is done through analysis and experimental manipulation.

[0105] How is it diagnosed? In one embodiment, a method of diagnosing renal disease in a subject is provided. The method comprises: determining the amount of cystatin B polypeptide in the sample, The amount of peptide is determined using one or more antibodies that specifically bind to SEQ ID NOs: 1-27. and determining the amount of cystatin B polypeptide in the sample relative to a control sample or control group. The level of cystatin B polypeptide in the sample is higher than that in the control sample or control standard. High levels are a sign of kidney disease.

[0106] Other methods can diagnose AKI or AKI in CKD patients. In an embodiment, the method comprises treating renal dysfunction or physical damage to the kidney caused by cancer or kidney cancer. In another embodiment, the method can be used to diagnose kidney disease caused by bacterial infection. , it can diagnose decreased kidney function or physical damage to the kidney. Bacterial infections can be the cause, e.g. For example, Anaplasma spp., Ehrlichia spp., Leptospira spp., Escherichia spp., or Borrelia It may be of type A.

[0107] In one embodiment of the present invention, the present invention relates to a method for treating renal disease, renal dysfunction, or physical damage to the kidney caused by bacterial infection. A method for diagnosing or detecting damage is provided, the method comprising: detecting cystatin in a sample from a subject; determining the amount of cystatin B polypeptide, No. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, One or more of the following: 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 determining using one or more antibodies that specifically bind to the polypeptide of The amount of cystatin B polypeptide in the sample is compared to a control sample or a control standard, and the sample is A higher level of cystatin B polypeptide in the cell culture medium compared to a control sample or control standard is It can be a sign of kidney disease caused by a bacterial infection, decreased kidney function, or physical damage to the kidneys.

[0108] The polypeptides disclosed herein are capable of detecting the activity of a non-disease subject in a sample from a diseased subject. It is found in an amount or at a level greater than that of a control sample from a subject. The relative levels of the polypeptides in the subject's sample are indicative of progression of the disease and disease severity. That is, in some cases, a higher amount or higher level of cystatin B Polypeptides indicate a more severe disease state.

[0109] A high level of cystatin B polypeptide is about 10% higher than the control sample or reference. 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, A high level of Cystatin B polypeptide is 500% or more higher. , about 10-500% or more, about 20-500% or more than the control sample or control standard or more, about 30-500% or more, about 40-500% or more, about 50-500% or more, about 60-500% or more, about 100-500% or higher level.

[0110] Also, a high level of cystatin B polypeptide refers to a sample that is high in a particular It may also be a level at which the amount is increased by a statistical significance.

[0111] In addition, a high level of cystatin B polypeptide is about 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 00, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,5 00, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8 ,000, 9,000, 10,000 ng / ml, or more. The control level or reference for the isoform of isoform of isoform of isoform of about 400, 350, 300, 250 , 200, 150, 100, 50, 20, 10 ng / ml or less.

[0112] High levels of Cystatin B polypeptide are associated with any type of kidney disease or condition. Control samples or samples determined using normal control subjects with no periodontal disease, bacterial infection, or periodontal disease. can be compared to a control standard.

[0113] In some embodiments, the level of Cystatin B polypeptide in the test sample is determined by measuring the level of Cystatin B polypeptide in one or more individuals. The levels of cystatin B in control samples from normal control subjects are compared. The control level measured in the control sample is compared with the cystatin B polypeptide level measured in the test sample. Alternatively, the level of Cystatin B polypeptide in the test sample is compared to The level is compared to a predetermined or predefined control level ("control standard"). A control for the IL-18 polypeptide may be derived from the data, e.g., multiple normal or healthy control subjects. Calculating from data including the level of cystatin B polypeptide in a control sample from The normal or healthy control subjects and the test subjects being evaluated can be of the same species.

[0114] In particular embodiments, in mammals, more particularly in dogs, cats, and humans, Reagents and methods are provided for identifying certain diseases or conditions. In one embodiment, a method is provided for providing a diagnosis and prognosis for a patient. Identification of these peptides may be an independent predictor of renal disease or a predictor of chronic kidney disease stage (e.g., The method may be an identifier of acute kidney injury or active kidney injury in any one of the following groups: Advantageously, the present invention enables the diagnosis and differentiation of acute kidney injury or active kidney damage in chronic kidney disease, and The method is not influenced or confounded by the age or weight of the subject. Using the aforementioned renal patient predictions determined using the polypeptide, appropriate renal therapy is determined. It is directed towards choosing.

[0115] Identification of Cys B polypeptide in a subject sample may be used to determine AKI grade (e.g., grade 1, grade 2, grade 3, grade 4, grade 5, grade 6, grade 7, grade 8, grade 9, grade 10, grade 11, grade 12, grade 13, grade 14, grade 15, grade 16, grade 17, grade 18, grade 19, grade 20, grade 21, grade 22, The methods and compositions described herein may be an independent predictor of grade 3 or 5 glaucoma. Advantageously, this allows for earlier diagnosis and identification of AKI stages, and is less sensitive to changes in patient age or weight. Not influenced or confounded.

[0116] The antibodies may be isolated from an animal, e.g., a human, cat, or dog, suspected of having kidney disease. The test sample can be used in a method for diagnosing kidney disease. under conditions that allow the formation of an antibody-antigen complex (i.e., an immune complex). Those skilled in the art will recognize the conditions that allow and are suitable for the formation of antigen / antibody complexes. The presence or amount of antibody-antigen complexes can be determined by methodologies known in the art. This can be done.

[0117] Embodiments further include the step of identifying levels of specific polypeptides in patient samples. to predict a patient's health status, monitor disease progression, and / or evaluate / monitor treatment efficacy In one embodiment, the method includes a method for assessing disease progression or treatment efficacy. In certain embodiments, the method is performed in a diagnostic setting. and then post-treatment identification of when a particular therapy should result in a reduction or amelioration of disease progression. The procedure can be carried out at any time.

[0118] The methods described herein also provide methods for determining the amount of a polypeptide comprising SEQ ID NO:1-27. In certain embodiments, the amount (nt) or quantity (quantity) of the The amount or quantity of a particular polypeptide is indicative of the stage of disease (i.e., stages 1-4). ), disease progression, and / or prognostic indicators. Many indicator reagents, such as enzyme conjugates, are used. When the antibody is present, the amount of polypeptide present is proportional to the signal generated. Depending on the circumstances, it may be diluted with a suitable buffer reagent, concentrated, or contacted with the solid phase without any manipulation. For example, pre-diluted serum or plasma samples, or concentrated samples such as urine, The condensed sample is used to determine the presence or amount of the polypeptide present. It is possible.

[0119] The polypeptides and assays described herein may be combined with other polypeptides or assays. In combination, the polypeptides and assays can be used to detect the presence of renal disease. , in combination with suitable reagents for detecting or measuring creatinine or general protein levels. It is possible to combine them.

[0120] In one embodiment, a method for distinguishing between an upper and a lower urinary tract infection is also provided. A lower urinary tract infection is an infection of the kidneys (pyelonephritis). A lower urinary tract infection is an infection of the bladder. These conditions can be difficult to distinguish. Their treatments may vary. Therefore, it is advantageous for medical professionals to know the difference between upper and lower urinary tract infections. There is a need in the art for methods to distinguish between these infections.

[0121] The method comprises determining the amount of cystatin B polypeptide in a sample from a subject, the amount of cystatin B polypeptide being determined by a method comprising the steps of: The method includes determining the amount of cystatin B in a sample using one or more antibodies that specifically bind to the cystatin B The amount of the polypeptide is compared to a control sample or a control standard, and the amount of the cystatin B polypeptide in the sample is determined. A higher level of urinary tract infection in a subject compared to a control sample or control standard is indicative of an upper urinary tract infection in a subject. It becomes a weather.

[0122] In one embodiment, a method is provided for distinguishing between acute kidney injury and a lower urinary tract infection. These conditions can be difficult to distinguish. Treatment for these conditions can vary, making it difficult for health care professionals to distinguish between the following: It would be advantageous to be able to distinguish between acute kidney injury and a lower urinary tract infection. determining the amount of cystatin B polypeptide in a sample from The amount of a polypeptide that specifically binds to one or more of the polypeptides consisting of SEQ ID NOs: 1-27 The method includes determining, using one or more antibodies, the amount of cystatin B polypeptide in a sample. The amount of the peptide in the sample is compared to a control sample or a control standard to determine the cystatin B polypeptide level in the sample. A higher level of creatine kinase activity relative to a control sample or control standard is indicative of acute kidney injury in the subject.

[0123] In one embodiment, a method for diagnosing periodontal disease in a subject is provided. These include gingivitis (inflammation of the gums) and periodontal disease. Periodontal disease is characterized by attachment loss and alveolar bone plaque formation. Periodontal disease is a destructive disease of the periodontal tissues. This is done by recognizing various signs and symptoms in the course of treatment. The appearance of signs and symptoms usually Long after the onset of the disease and substantial damage to the supporting bones and tissues has occurred Furthermore, periodontal disease cannot be adequately evaluated or treated in veterinary patients without general anesthesia. There is a need in the art for a method for early detection of periodontal disease. The method includes determining the amount of cystatin B polypeptide in a sample from a subject. The amount of Cystatin B polypeptide comprises one or more antibodies specific for SEQ ID NOs: 1-27. The amount of cystatin B polypeptide in the sample is determined using a control sample or a control group. The level of cystatin B polypeptide in the sample is higher than that in the control sample or control standard. A high level of creatinine is indicative of periodontal disease in a subject.

[0124] Treatment method In certain embodiments, a method of treating a disease condition in a subject is provided. The method comprises: determining the amount of cystatin B polypeptide in a sample from a subject by using one of the antibodies specific for numbers 1-13; This includes requiring a test to provide an analytical result for the determination using the above antibodies. The amount of cystatin B polypeptide contained in the sample is determined based on the amount of the control sample or control standard for the disease state. If the IL-10 level is higher than IL-10, then the subject is administered treatment for the disease condition.

[0125] Disease conditions include AKI, periodontal disease, upper urinary tract infections, and renal disease. In this case, the disease state is not cancer or kidney cancer.

[0126] Treatment of CKD, AKI, and renal disease includes, for example, treatment of obstructed nephron / ureteral stones. Surgery, chemotherapy for renal neoplasia, dietary management, intestinal phosphate binders, antiproteinuric drugs (e.g. , angiotensin-converting enzyme inhibitors (ACEIs), omega-3 fatty acids), antihypertensives (e.g. ACEI, calcium channel antagonists (CCA), fluid therapy to correct dehydration, Management of idiopathies, administration of diuretics, dialysis, correction of electrolyte abnormalities, antiemetics and antacids, recombinant Upper urinary tract infections can be treated with antibiotics. Periodontal disease can be managed with thorough cleaning, scaling, and root planning. ning, gum graft surgery, laser treatment, regenerative procedures (membranes in pockets (fills tator), bone graft, or use of tissue stimulating proteins), dental implants, pockets Reduction procedures (folding back of gingival tissue and removal of disease-causing bacteria before fixing the tissue back in place) ) can be treated.

[0127] In an alternative embodiment, the methods described herein are used to prepare compositions or treatment regimes. The effectiveness of the (composition or diet) in improving disease progression can be evaluated. Using the methods described herein, patient levels of a polypeptide comprising SEQ ID NO: 1-27 may be determined. The activity of a composition or treatment regimen against the

[0128] kit In one embodiment, a kit is provided for carrying out the methods described herein. In one embodiment, the kit comprises one or more polypeptides comprising SEQ ID NOs: 1-27. Optionally, in certain embodiments, the method comprises the step of: In addition to instructions, a secondary antibody useful in, for example, a sandwich assay, can be included. A specific labeled antibody may also be present in the kit, as well as reagents for labeling the antibody.

[0129] In a further embodiment, the kit comprises one or more polypeptides each comprising SEQ ID NOs: 1-27. In certain embodiments, the antibody or antibodies specifically bind to the peptide. The bodies may be solid supports or microarrays, including, but not limited to, chips, microarrays, beads, etc. It is provided on a substrate.

[0130] The kit (e.g., article of manufacture) may include a kit for detecting a polypeptide or polypeptides described herein in a patient sample. The kit may be for detecting a protein fragment thereof. Determining the binding of the antibody to the full-length protein or protein fragments described herein The kit or article of manufacture also includes a composition comprising one or more antibodies or antibody fragments, Also included are compositions for determining the binding of the antibody or antibody fragment to a polypeptide in a sample. The kit may include a device containing one or more polypeptides or antibodies, Instructions for use of the one or more polypeptides or antibodies may be provided, for example, for treating renal disease in a mammal. The kit may also include one or more polypeptides of the kit. or a label indicating that the antibody can be used to identify renal dysfunction. The antibody may also contain packaging materials containing other components known to those of skill in the art, such as buffers, controls, etc. Components that may be included in such test kits include the polypeptides, antibodies, The assays and kits are useful, for example, for diagnosing renal disease in individual cases in patients.

[0131] The kits are intended to diagnose, predict, or treat kidney disease, particularly in dogs, cats, and humans. is useful to monitor.

[0132] The embodiments illustratively described herein include any The present invention may be suitably practiced in the absence of one or more of the elements or one or more of the limitations described above. For example, in each instance herein, the terms "comprising," "consisting essentially of," and " and "consisting of" may be used interchangeably with the other two terms while retaining their ordinary meaning. The terms and expressions used are for explanatory purposes only. and the use of such terms and expressions is intended to be consistent with the principles of the present invention and is not intended to be limiting. It is not intended to exclude equivalents of the features or portions thereof, and the claimed embodiments It is recognized that various modifications are possible within the scope of the present invention. Although specifically disclosed by the embodiments, the options in the concepts disclosed herein are not intended to be limiting. It is understood that the features, modifications, and variations described herein may be utilized by those skilled in the art and that such modifications and variations may be utilized by those skilled in the art. Such modifications and variations are intended to be included within the spirit and scope of the present invention as defined by this specification and the appended claims. It should be understood that this is considered within the scope of the embodiments.

[0133] Method embodiments incorporating the above-mentioned features are intended to fall within the scope of this disclosure. EXAMPLES

[0134] The following examples are illustrative of certain embodiments of the present disclosure and various applications thereof. These examples are presented for illustrative purposes only and should not be construed as limiting. .

[0135] Example 1: Protein sequence of dog Cys B Previously, canine Cys B had a protein sequence of 77 aa as shown in SEQ ID NO:1. It was thought that... QVKAQLEERENKKYTTFKAVTFRSQVVAGTPYFIKVQVDD DEFVHLRVFQSLPHENKPLALSSYQTNKAKHDELAYF (array Number 1) However, this idea is incorrect. MDCK cell lines were grown to confluency and adherent. The cells were harvested and lysed in a physiological buffer containing a detergent. After lysis, the cells were The supernatant was then spun at 1,000 rpm for 30 minutes to pellet the cell debris. The supernatant was used as a source of cystatin B. The N-terminus was sequenced using trypsin digestion and LC-MS identification. MMCGAPSASQPATADTQAIAD (SEQ ID NO: 2) Therefore, the complete amino acid sequence of canine Cys B (FL-Cys B) is as follows: It has been decided. MMCGAPSASQPATADTQAIADQVKAQLEERENKKYTTFKA VTFRSQVVAGTNYFIKVQVDDDEFVHLRVFQSLPHENKPL ALSSYQTNKAKHDELAYF (SEQ ID NO:3)

[0136] Example 2: Antibodies against canine cystatin B A. Antibody production against recombinant proteins Recombinant sequences of SEQ ID NO:1 and SEQ ID NO:3 were used as immunogens according to standard methodologies in rabbits. Polyclonal antibodies were generated by using the same proteins. Antibodies were generated that specifically bound to each recombinant immunogen in an ELISA assay. .

[0137] Recombinant tandem with SEQ ID NO:3 as immunogen was cultured according to standard methodology in mice. The protein is used in combination with the adjuvant CPG to produce monoclonal antibodies. The seven antibodies were shown to specifically bind to their respective recombinant immunogens in an ELISA assay. Monoclonal antibodies were generated using HRP-goat anti-mouse IgG heavy and light chain secondary antibodies. All clones tested were immunoreactive with 5ug / ml recombinant FL cystatin. B (SEQ ID NO:3) coated plates. Table 4 shows the results of three of the clones. Exemplary binding data for one of the samples is shown.

[0138] [Table 5]

[0139] B: Antibody production against synthetic peptides The following peptides derived from canine cystatin B were conjugated to KLH. The conjugates were then incubated with rabbit antibodies. It was used as an immunogen for antibody production.

[0140] Cystatin BC terminus "peptide 9" QTNKAKHDELAYF (SEQ ID NO: 4) Cystatin B N-terminal "peptide 3-20" CGAPSASQPATADTQAIA( SEQ ID NO:5) Cystatin B N-terminus "peptide 3-10" CGAPSASQ (SEQ ID NO:6) Cystatin B N-terminus "peptide 18-25" CAIADQVKA (SEQ ID NO: 7) Cystatin B "Peptide 2" FQSLPHENKPLALSS (SEQ ID NO: 8) Cystatin B "Peptide 1" SQVVAGTPYFIKVQVDDD (SEQ ID NO: 9)

[0141] Additionally, SEQ ID NO:2 (N-terminus) was used as an immunogen according to standard methodologies in mice. and peptide of SEQ ID NO:5 (peptide 3-20) with Freund's adjuvant. By this method, polyclonal and monoclonal antibodies were produced. Antibodies were generated that specifically bind to each recombinant immunogen in an ELISA assay. Ta.

[0142] Thus, each antibody was generated to specifically bind to its respective peptide immunogen. For example, Table 5 below shows the results of the rabbit anti-peptide polyclonal antibody binding to peptides 1, 2, The typical binding curves of 9 and 9 with each immunogen are shown. All of the antibodies bound to the target with high affinity and were then used in cystatin B ELISA. SA can be used to form sandwiches.

[0143] [Table 6]

[0144] Furthermore, anti-peptide 9 and anti-peptide 1 antibodies were found to inhibit stimuli in ELISA assays. Recombinant FL-Cys B (SEQ ID NO: 3) and Ne in lysates of stimulated MDCK cells Anti-peptide 9 antibody specifically bound to the native intracellular protein. Specific binding to peptide KHDELAYF (SEQ ID NO: 10) in the assay was shown.

[0145] SEQ ID NOs: 11, 12, and 13 were used to immunize rabbits according to standard methodology. Each antibody bound specifically to its respective antigen in an ELISA assay.

[0146] Example 3: Immunoassay for the detection of canine cystatin B A cystatin B ELISA was developed as follows. Solid phase and capture antibodies: A 96-well 4BX microtiter plate was filled with 10ug / ml of affinity purified ELISA. Plates are coated with Heron anti-peptide 9 overnight at 4° C. with 0.05% TWEE Wash three times with 1x PBS, pH 7.4, containing N® (polysorbate) 20. The plates are then blocked with 1x PBS, pH 7.4, containing 1% BSA for 2 hours. After washing as above, the plates are dried under vacuum at 37°C for 4 hours. The plates are stored dry at 4°C.

[0147] Preparation of detection antibody: From mice immunized with full-length recombinant cystatin B (rFL-Cys B) (SEQ ID NO: 3) We generated seven monoclonal antibodies to determine their binding performance against rFL Cys B. One clone (3H4) was selected based on the sequence and purified using protein G to give a 1.0 1 mg of purified antibody was purified using the SMCC method with horseradish peroxidase (HR The antibody was labeled with 0.25-2.0 P and desalted to remove excess HRP. ug / ml was used in the ELISA assay.

[0148] Cystatin B sandwich ELISA protocol: serum and urine Cystatin B is an intracellular protein and generally does not circulate freely in high concentrations. This was confirmed by the finding of a protein in the supernatant collected from stressed dog kidney cells. This was further confirmed by the fact that cystatin B was not detected in the destroyed dogs. Cystatin B was purified from kidney cells. Therefore, any cystatin B detected in serum was not associated with this destruction. This may be due to cell necrosis or cell death. Apoptosis and necrosis may result in increased serum and urinary cystatin B. There is (Figure 1).

[0149] Cystatin B has not been associated with renal disease in companion animals. We produced monoclonal antibodies against recombinant cystatin B and confirmed their specificity by comparing them with those against cystatin C. The presence of these proteins was confirmed by Western blot analysis (Figure 2). A sandwich ELISA was also developed using this antibody.

[0150] The standards for the sandwich ELISA were rFL-Cys B or MDCK cell pellets. Both standard preparations were quantified by LCMS. Urine samples were diluted in buffer A (0.1 M PO4; pH 7.4, containing at least 0.1% sarcosine). Serum samples were diluted at least 1:10 in buffer A (containing 100 mM triglyceride). Both were diluted 1:100 and 100ul was added to duplicate wells as above. Add 100 microliters (100 ul) in duplicate to the polyclonal antibody capture wells. The plate was then incubated at room temperature for 1 hour with shaking. Detergent (IDEXX Laboratories, Inc., Maine, US) Wash 6 times with A) and incubate with 100ul of 0.25-2ug / ml HRP monoclonal detection antibody. The detection antibody was added and incubated for 30 minutes with shaking, then washed six times. 100 ul of substrate TMB was added to the wells. Color was developed for 5 minutes, followed by 100 ul of stopping Stopping solution (1N HCL) was added. The plate was then placed on a VMAX® Microplate Reader. The unknowns were read using the 4PL parameter fit in Sigma plot. was quantified.

[0151] Native canine cystatin B (MDCK lysate) was used to assay Cystatin B as described above. A standard curve was obtained with the s B ELISA assay (Figure 3).

[0152] Detection of canine cystatin B in patient samples. Cystatin B in dog urine was detected using the cystatin B ELISA assay as described above. The levels were determined and are shown in Table 6.

[0153] [Table 7]

[0154] As shown in Table 6, healthy dogs had acute (active) kidney injury (AKI) and chronic kidney disease ( The AKI samples had lower urinary cystatin B levels than the CKD samples. showed higher cystatin B levels than control.

[0155] Cystatin B ( Fig. 4) and urinary system data from dogs presented to the clinic with inflammation- or ischemia-induced active renal damage. In a model system, serum creatinine was measured at 1.5 mg / kg / day for dogs. Gentamicin was administered at 10 mg / kg every 8 hours until the blood glucose concentration reached 10 g / dL. In dogs, this point was reached on day 8, while serum cystatin B was at baseline on day 1. These preliminary results suggest that cystatin B may be a critical predictor of active renal damage. It is suggested that creatinine is an earlier marker than creatinine. A clear segregation was observed between patients diagnosed with active renal disease.

[0156] Example 4: Cystatin B detection by oral swab Cotton swabs were used to sample the gingiva of dogs undergoing dental examinations. showed gingivitis, gum disease, and even severe tooth decay. The swabs were placed in plastic test tubes. The swabs were equilibrated to room temperature for 30 minutes and then decontaminated with detergent. The swabs were then placed in 0.5 ml of Cystatin B assay buffer for 30 minutes. A control swab without sample was used in the Cystatin B assay described above. The control swabs were used to determine the null. The control swabs were below the limit of detection (LOD) with a mean OD of 0.04. In contrast, the OD of a swab from a dog that had undergone extensive dental procedures was 1.04. This gives a signal to noise ratio of 26. See Table 7 below.

[0157] [Table 8]

[0158] The teeth of two dogs with periodontal disease were swabbed with cotton swabs and cystatin B ELI was examined. Cystatin B was extracted in SA buffer and subjected to the cystatin B assay as a sample. The positive control was a standard sample spiked with 0.00 ng / ml of recombinant full-length canine cystatin B protein. The signal (OD at 450 nM) was determined by the recombinant full-length canine cysteine. 0.322 for Chin B protein positive control, 1.8485 for Dog 1, and 1.099 for Dog For 2, the value was 1.444. The values ​​for the two dogs with periodontal disease were 1000 ng / 5-fold higher than the canine FL-Cys B standard at 1 ml. It is a marker for periodontal disease in mammals such as dogs.

[0159] Example 5: Modified ELISA 96-well 4BX microtiter plates were filled with 5 μg / ml affinity purified rabbit Plates were coated with anti-peptide 9 overnight at 4° C. The plates were then incubated with 0.05% Wash three times with 1x PBS containing TWEEN® (polysorbate) 20. The plates were then blocked for 2 hours with 1x PBS, pH 7.4, containing 1% BSA. After washing as above, the plates are dried under vacuum at 37°C for 4 hours. Store the pellet dry at 4°C.

[0160] The standards for the sandwich ELISA were rFL-Cys B or MDCK cell pellets. Both standard preparations were quantified by LCMS. The urine samples were diluted with Buffer A (0.1 M phosphate, pH 7.2, containing at least 1.0% N-dodeca containing sodium noyl-N-methylglycine (Sarkosyl, Sigma) Serum samples were diluted at least 1:50 in buffer A and diluted 1:20. 100 microliters (100 ul) was added to the wells in duplicate as above. ) were added in duplicate to the polyclonal antibody capture wells and incubated at room temperature with shaking for 1 hour. The plates were then washed with PETCHEK® Detergent (IDEXX L The samples were washed six times with 100 mL of 100 mL of 100% ethanol (Aboratories, Inc., Westbrook, Maine, USA). Wash and add 100ul of 0.25-2ug / ml HRP-conjugated monoclonal detection antibody. The detection antibody was incubated for 30 min with shaking, then washed six times and added 100 μl 1 μl of substrate TMB was added to the wells. Color was developed for 5 minutes, followed by 100 μl of stop solution ( 1N HCL) was added. The plate was read using a VMAX® microplate reader. Read. Quantify the unknowns using 4PL parameter fits in Sigma plot. did.

[0161] Example 6: Detection of Human Cys-B In this example, an ELISA was performed to detect human Cys B using an anti-canine Cys B antibody. Demonstrate the construction of SA. Recombinant human cystatin B (rHFL Cys B) protein (SEQ ID NO: 14) was obtained from Genscript, USA. >sp|P04080|CYTB_Human Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 MMCGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKA VSFKSQVVAGTNYFIKVHVG DEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF [ SEQ ID NO:14]

[0162] Cross-reactivity of rH FL Cys B protein with antibodies raised against canine cystatin B Reactivity was assessed by sandwich ELISA. A mouse monoclonal antibody raised against a cystatin B sequence (rC FL cystatin B). was used as a capture reagent to bind multiple recombinant FL Cys B antigens in ELISA. The detection reagents screened were rabbit polyclonal N-terminal Anti-canine cystatin B antibody and horseradish peroxidase anti-species IgG (H&L A series of reagent pairs were found that produced dose-dependent curves in ELISA. As shown in Table 8 below, the canine C-terminal "peptide 9" (QTNKAKH Three monoclonal antibodies (IF10, 2B 5, and 9A10) were incubated with anti-dog N-terminal cystatin B polyclonal antibody 327 (rabbit 7) in rabbits), 328 (raised against CAIADQVKA (SEQ ID NO: 7) in rabbits), PSASQPATADTQAIA (SEQ ID NO: 5)), or 329 (raised in rabbits In the present study, the sandwich E These pairs were then used to generate the LISA. bound to the protein.

[0163] [Table 9]

[0164] Canine cystatin B was detected using N-terminal rabbit polyclonal antibody 327 as a solid-phase capture. Monoclonal antibody generated against C-terminal "peptide 9" QTNKAKHDELAYF (SEQ ID NO: 4) Clonal mouse antibodies were analyzed for binding to rHFL Cystatin B. See Table 9. As shown in Table 10 below, a C-terminal monoclonal antibody (9A10) was whereas another C-terminal monoclonal antibody (2B5) formed a sandwich. The specificity of these monoclonal antibodies was mapped, and the 9A10 monoclonal antibody NAL recognized the homologous sequence of both human and canine cystatin B. rFL canine cystatin B The 3H4 monoclonal antibody was raised against and paired with the solid-phase-bound polyclonal antibody 327. The rFL antibody demonstrated binding to both human and canine rFL Cystatin B (Table 11).

[0165] [Table 10]

[0166] [Table 11]

[0167] [Table 12]

[0168] Antibodies specific for canine Cys B can be used to detect human Cys-B. Particularly AYF, LAYF (sequence number 20), ELAYF (sequence number 21), DELAYF (SEQ ID NO: 22), HDELAYF (SEQ ID NO: 23), KHDELAYF (SEQ ID NO: 10 ), AKHDELAYF (SEQ ID NO: 24), KAKHDELAYF (SEQ ID NO: 25), N KAKHDELAYF (SEQ ID NO: 26), TNKAKHDELAYF (SEQ ID NO: 27), and QTNKAKHDELAYF (SEQ ID NO: 4), or a portion thereof. The antibody or its specific binding fragment can be used to detect Cys B in humans and dogs. can be done.

[0169] Example 7: Determination of reference ranges in dog and cat urine Urine samples from dogs and cats were collected at a local veterinary clinic over a two-year time frame. Urine was aliquoted and frozen until use. Cystatin B was measured in urine samples collected from the rabbit. Kidney problems, such as attenuin or SDMA levels, and history or symptoms of urinary stones or urinary tract infections A reference range was established from healthy animals with no signs of harm. Thus, a total of 280 Healthy dogs and 42 healthy cats were used, and the mean ± 3 standard deviations (Std Dev) for each species was 1. v) was used to determine the reference range of 257ng / ml. See Figure 6. A healthy range is from about 0 ng / ml to about 257 ng / ml (e.g., about 0, 5, 10, 20, 50, 75, 100 to about 200, 210, 225, 250, or 257 ng / ml) Values ​​above 257 ng / ml (e.g., about 257, 260, 270, 280, 2 90, 300 ng / ml and above) are signs of kidney disease.

[0170] Example 8: Cystatin B in canine AKI populations Twenty-five matched urine samples from dogs with clinically confirmed AKI and healthy dogs were collected. Serum samples were subjected to Cystatin B ELISA (Example 5). Etiology of AKI patients includes: Examples include nephrotoxic drugs, snakebites, heatstroke, ethylene glycol exposure, and infections. As shown in Figure 7A-B and Table 12-13, the urinary and and serum cystatin B levels were significantly increased compared to healthy dogs and CKD patients.

[0171] [Table 13]

[0172] [Table 14]

[0173] Example 9: Cystatin B in infectious diseases The most common infectious disease in the urinary system of animals is infection with aerobic bacteria. Organisms include E. coli, Staphylococcus, Enterococcus, and Streptococcus. Organisms that cause bacterial infections include Klebsiella, Proteus, and Pseudomonas. Mycoplasma is a rare cause of urinary tract infections and is usually associated with bacteria. Leptospirosis is a zoonotic disease found worldwide. It is caused by filamentous Leptospira bacteria that infect the kidneys and many other organs. Rickettsiosis and related diseases (Anap The causes of scrub typhus (ehrlichiosis, Q fever, and scrub typhus) are gram-negative obligate intracellular rod-shaped bacteria. Babesia, a tick-borne disease, has also been implicated in kidney disease.

[0174] ELISA, PCR, and microscopic agglutination test (MAT) titers >1:800 (IDEXX Twenty specimens were identified as positive for Leptospira spp. by the National Institute of Infectious Diseases (NIID) Laboratories, Inc. Serum samples from the canine patients were subjected to Cystatin B ELISA. Dog serum samples were also subjected to ELISA to determine the mean serum cystatin B levels. As shown in Table 14 of the present study, nine leptospirosis-positive samples (45%) were from healthy dogs. The serum relative cutoff value (mean + 3SD) (149.1 ng / ml) was exceeded (Figure 10 The data show that 45% of leptospirosis patients tested had renal involvement. Therefore, high serum levels of cystatin B are associated with Leptospira infection. This indicates the presence of kidney damage in livestock.

[0175] [Table 15]

[0176] Example 10: Cystatin B in urinary tract infections Urine samples from 10 dogs with clinically confirmed urinary tract infection (UTI) and 1 A healthy cohort of 0 animals was subjected to cystatin B assay. UTI was defined as positive culture and clinical The interference from UTI was significant relative to the specificity of known AKI markers. Figure 8 shows the relationship between cystatin B levels in healthy animals and animals with urinary tract infections. Therefore, the cystatin B marker did not show any significant difference. can be used to distinguish between AKI and UTI.

[0177] Example 11: Cystatin B in feline kidney disease Urine samples from four cats diagnosed with renal disease and three healthy cats were obtained from a local veterinary clinic. These were subjected to a cystatin B assay. The urinary cystatin B concentration in the three healthy dogs was above the reference range of 257 ng / ml. The urinary cystatin B concentrations in each cat were within the reference range. See Table 15. Statin B is a marker of renal disease in cats.

[0178] [Table 16]

[0179] Example 12: Anti-Cystatin B Antibodies in Sheep Two sheep were used to generate sheep polyclonal antibodies against SEQ ID NO:4. The peptide was conjugated to KLH and emulsified in Freund's complete adjuvant. The antibody responses in sheep serum were compared with those in rabbit serum. Similar titers were seen in sheep, even though it was early in the vaccination protocol. Antibodies produced in A. rhododendron can be used to detect Cys B polypeptides.

[0180] [Table 17]

[0181] Example 13: Human urinary cystatin B detection in CKD patients Urine was collected from a human patient diagnosed with stage 4 CKD. The urine was subjected to cystatin B ELISA. Two anti-cystatin B monoclonal antibodies (3H4 ( As shown in FIG. 9, human Urine samples produced higher levels of cystatin B than canine AKI samples and lower levels than canine negative controls. Furthermore, a different anti-cystatin B monoclonal antibody was used, possibly showed different responses due to the binding availability of the epitopes. Renal disease can be diagnosed in humans using antibodies specific for cystatin B.

Claims

1. 1. A method for detecting a cystatin B polypeptide in a sample, comprising contacting the sample with one or more antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NO:2, 5, 6, 7, 11, or 12 under conditions suitable for the formation of a complex between the cystatin B polypeptide and the one or more antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NO:2, 5, 6, 7, 11, or 12, and detecting the complex between the cystatin B polypeptide and the one or more antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NO:2, 5, 6, 7, 11, or 12.

2. 1. A method for diagnosing renal disease in a non-human subject, comprising: (a) determining the amount of Cystatin B polypeptide in a sample from the non-human subject, wherein the amount of Cystatin B polypeptide is determined using one or more antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NOs: 2, 5, 6, 7, 11, or 12; and (b) comparing the amount of Cystatin B polypeptide in the sample with a control sample or control standard, wherein a higher level of Cystatin B polypeptide in the sample compared to the control sample or control standard is indicative of kidney disease.

3. A method of treating renal disease in a non-human subject, comprising: calling for a test to provide the result of an analysis for determining the amount of cystatin B polypeptide in a sample from the non-human subject using one or more antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NOs: 2, 5, 6, 7, 11, or 12; and administering to the non-human subject a treatment for reduced renal function if the sample contains a higher amount of cystatin B polypeptide compared to a control sample or control standard for the renal disease.

4. 1. A method for diagnosing periodontal disease in a non-human subject, comprising: (a) determining the amount of Cystatin B polypeptide in a sample from the non-human subject, wherein the amount of Cystatin B polypeptide is determined using one or more antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NOs: 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27; and (b) comparing the amount of Cystatin B polypeptide in the sample with a control sample or control standard, wherein a higher level of Cystatin B polypeptide in the sample compared to the control sample or control standard is indicative of periodontal disease in the non-human subject.

5. 1. A method for distinguishing between an upper and lower urinary tract infection, comprising: (a) determining the amount of a cystatin B polypeptide in a sample from the non-human subject, wherein the amount of the cystatin B polypeptide is determined using one or more antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NOs: 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27; and (b) comparing the amount of Cystatin B polypeptide in the sample with a control sample or control standard, wherein a higher level of Cystatin B polypeptide in the sample compared to the control sample or control standard is indicative of an upper urinary tract infection in the non-human subject.

6. 1. A method for distinguishing between acute kidney injury and a lower urinary tract infection, comprising: (a) determining the amount of a cystatin B polypeptide in a sample from the non-human subject, wherein the amount of the cystatin B polypeptide is determined using one or more antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NOs: 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27; and (b) comparing the amount of Cystatin B polypeptide in the sample with a control sample or control standard, wherein a higher level of Cystatin B polypeptide in the sample compared to the control sample or control standard is indicative of acute kidney injury in the non-human subject.

7. 4. The method of claim 2 or 3, wherein the cause of the kidney disease is acute kidney injury or active kidney injury in a patient with chronic kidney disease, progressive chronic kidney disease, acute kidney injury, active kidney injury, or bacterial infection.

8. The method of claim 2 or 3, wherein the kidney disease is not caused by cancer.

9. 8. The method of claim 7, wherein the bacterial infection is caused by an Anaplasma species, an Ehrlichia species, a Leptospira species, an Escherichia species, or a Borrelia species.

10. The method of claim 1, 2, 3, 4, 5, or 6, wherein the amount of Cystatin B polypeptide is determined by detecting a complex between Cystatin B polypeptide and the one or more antibodies that specifically bind to the one or more polypeptides.

11. The method of any one of claims 1, 2, 3, 4, 5, or 6, wherein the antibody is immobilized on a solid support.

12. The method of any one of claims 1, 2, 3, 4, 5, or 6, wherein the antibody is conjugated to one or more labels.

13. 11. The method of claim 10, further comprising contacting the complex of a cystatin B polypeptide and one or more antibodies specific for the one or more polypeptides with an indicator reagent.

14. 7. The method of any of claims 1, 2, 3, 5, or 6, wherein the sample is blood, serum, plasma, or urine.

15. The method of claim 4, wherein the sample is saliva, plaque, gingival crevicular fluid, a gingival biopsy, or a tongue swab.

16. The method of any of claims 1, 2, 3, 4, 5, or 6, wherein the amount of the cystatin B polypeptide or cystatin B polypeptide is determined or detected by an immunoassay, a competitive immunoassay, a sandwich immunoassay, an enzyme-linked immunosorbent assay (ELISA), an immunoturbidimetric assay, a particle-enhanced immunoturbidimetric assay, a radioimmunoassay (RIA), or a Western blot assay.

17. An isolated antibody which specifically binds to one or more polypeptides consisting of SEQ ID NO:2, 5, 6, 7, 11, or 12.

18. The isolated antibody, (a) freeze-dried, powdered or desiccated; (b) linked to a label; (c) immobilized on a solid support; (d) specifically binds to a polypeptide consisting of SEQ ID NO: 2, 5, 6, 7, 11, or 12; or (e) the isolated antibody of claim 17, which is immobilized on a solid support and specifically binds to a polypeptide set forth in SEQ ID NO: 2, 5, 6, 7, 11, or 12.

19. 1. A kit for diagnosing kidney disease, acute kidney injury or active kidney injury in a patient with chronic kidney disease, acute kidney injury, active kidney injury, progressive chronic kidney disease, upper urinary tract infection, or periodontal disease, comprising: (a) one or more antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NO: 2, 5, 6, 7, 11, or 12; and (b) a kit comprising one or more reagents that enhance the binding of said one or more antibodies to a Cystatin B polypeptide present in a sample from a non-human subject.

20. One or more isolated polypeptides consisting of SEQ ID NO:2, 5, 6, 7, 11, or 12.

21. The polypeptide, (a) freeze-dried, powdered or desiccated; (b) linked to a label; (c) immobilized on a solid support; (d) one or more isolated polypeptides of claim 20 that specifically bind to one or more antibodies that specifically bind to one or more polypeptides set forth in SEQ ID NOs: 2, 5, 6, 7, 11, or 12.

22. 1. An immune complex comprising: (i) one or more isolated antibodies that specifically bind to one or more polypeptides consisting of SEQ ID NO: 2, 5, 6, 7, 11, or 12; and (ii) one or more polypeptides that specifically bind to the one or more isolated antibodies.

23. The immune complex of claim 22, which is immobilized on a solid support.

Citation Information

Patent Citations

  • Markers for kidney disease

    JP2013527478A

  • Methods for detection of acute kidney injury in humans

    WO2010057184A2

  • Compositions and methods for diagnosing and treating kidney disorders in a canine

    WO2011079280A2

  • Markers for renal disease

    WO2011153469A1

Cited By

  • Methods and compositions for detection and diagnosis of renal disease and periodontal disease

    JP2024028816A